Prelude Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,132
Closed -$236K 1193
2025
Q1
$236K Buy
+2,132
New +$236K 0.02% 740
2022
Q4
Sell
-1,948
Closed -$207K 1375
2022
Q3
$207K Buy
+1,948
New +$207K 0.01% 1034
2020
Q4
Sell
-1,538
Closed -$148K 1284
2020
Q3
$148K Buy
1,538
+1,473
+2,266% +$142K 0.01% 576
2020
Q2
$8K Buy
+65
New +$8K ﹤0.01% 1099
2019
Q2
Sell
-498
Closed -$44K 1553
2019
Q1
$44K Buy
498
+259
+108% +$22.9K ﹤0.01% 817
2018
Q4
$17K Sell
239
-11,805
-98% -$840K ﹤0.01% 941
2018
Q3
$1.48M Sell
12,044
-3,141
-21% -$386K 0.09% 167
2018
Q2
$1.49M Sell
15,185
-3,553
-19% -$349K 0.09% 174
2018
Q1
$1.55M Buy
18,738
+4,033
+27% +$334K 0.11% 146
2017
Q4
$1.14M Sell
14,705
-28,554
-66% -$2.22M 0.09% 196
2017
Q3
$2.65M Buy
43,259
+9,241
+27% +$566K 0.24% 79
2017
Q2
$1.57M Buy
34,018
+13,493
+66% +$621K 0.15% 130
2017
Q1
$889K Buy
20,525
+3,699
+22% +$160K 0.09% 229
2016
Q4
$651K Sell
16,826
-11,560
-41% -$447K 0.08% 255
2016
Q3
$1.44M Buy
28,386
+21,825
+333% +$1.1M 0.15% 142
2016
Q2
$298K Sell
6,561
-500
-7% -$22.7K 0.04% 361
2016
Q1
$279K Buy
7,061
+367
+5% +$14.5K 0.04% 378
2015
Q4
$379K Sell
6,694
-1,400
-17% -$79.3K 0.06% 309
2015
Q3
$322K Buy
8,094
+6,794
+523% +$270K 0.05% 358
2015
Q2
$62K Buy
1,300
+800
+160% +$38.2K 0.01% 997
2015
Q1
$20K Buy
+500
New +$20K ﹤0.01% 1674
2014
Q4
Sell
-2,500
Closed -$39K 1950
2014
Q3
$39K Sell
2,500
-5,000
-67% -$78K 0.01% 1372
2014
Q2
$111K Sell
7,500
-13,700
-65% -$203K 0.01% 941
2014
Q1
$341K Buy
+21,200
New +$341K 0.05% 477
2013
Q4
Sell
-1,500
Closed -$17K 1681
2013
Q3
$17K Buy
+1,500
New +$17K ﹤0.01% 1106